Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

The Saudi Food and Drug Authority (SFDA) has approved Agios' Pyrukynd (mitapivat) for adults with alpha or beta-thalassemia.

Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.

Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.

Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) to ...

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Fresh off his appointment as the head of the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), Dr George Tidmarsh has been signed in as temporary director of the ...